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SHORT REPORT
Ibutilide for treatment of atrial fibrillation in the emergency
department
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The purpose of this study was to assess the efficacy and safety
of ibutilide, a class III antiarrhythmic drug, for acute treatment
of atrial fibrillation (AF) in the emergency department (ED)
setting. A retrospective analysis was done reviewing all
patients with AF who received ibutilide in the ED in a
university hospital setting. A total of 22 patients received
ibutilide. Another 24 patients who received rate control
drugs only served as a control group. Of the 22 patients who
received ibutilide, 14 (64%) converted to sinus rhythm. The
mean (SD) rate of AF was 137 (24) bpm and the mean QTc
interval immediately after conversion to sinus rhythm was
420 (28) ms. There were no complications. In the rate control
group 7 patients (29%) converted to sinus rhythm (p,0.05,
compared with ibutilide). The mean rate of AF was 126
(26) bpm (p = ns, compared with ibutilide) and the mean QTc
interval in those who converted was 377 (28) ms (p,0.05,
compared with ibutilide). One patient developed severe
bradycardia. Ibutilide is effective for conversion of recent
onset AF in patients presenting to the ED and there is a low
rate of complications from ibutilide in this setting.
A
trial fibrillation (AF) is an arrhythmia commonly
encountered in the emergency department (ED).
Patients come to the ED with different clinical
presentations of AF and the best treatment strategy varies,
depending on number of factors. Among those who have a
recent onset (,48 hours) of AF the most advantageous
strategy may be restoration of sinus rhythm.1
Ibutilide is a class III antiarrhythmic drug which is only
available in the intravenous form. It is approved for
conversion of recent onset AF and atrial flutter.2 As is the
case with other class III antiarrhythmic drugs ibutilide
increases the risk of prolongation of the QT interval,2 which
can predispose the patient to torsades de pointes. The risk of
torsades de pointes with ibutilide is approximately 7–8% with
2–3% being sustained.2
We undertook this study to compare ibutilide with the
strategy of giving rate control drugs only to those patients
who presented to the ED with recent onset AF (,7 days) and
were in the non-fasting state, and therefore not candidates
for immediate electrical cardioversion. We also aimed to
assess the safety of ibutilide administration in the ED setting.
METHODS
Study design
We performed a retrospective analysis of all patients who had
received ibutilide for AF in the ED between 2000 and 2003.
For comparison we included a group of patients with recent
onset AF treated with rate control drugs. The choice of
treatment for each patient was at the discretion of the
attending physician.
Study setting, population, and drug dosing
The Icelandic Data Protection Authority and the Landspitali
University Hospital Institutional Review Board gave permis-
sion for the undertaking of this study. As this was a
retrospective study, the Institutional Review Board did not
require written informed consent from the participants.
This study was undertaken in the university hospital’s
Hringbraut campus emergency room where cardiac patients
are treated. In our ED there are strict exclusion criteria for the
use of ibutilide, which were set when ibutilide use began.
Those patients with a decreased ejection fraction of the left
ventricle, a history of long QT interval, AF with slow
ventricular response (,65 bpm), or electrolyte disturbances,
or those taking other QT prolonging drugs are excluded from
receiving the drug. This is to minimise the risk of serious
adverse effects of the drug, especially torsades de pointes.3
Ibutilide dosing is as follows: 1 mg given intravenously over
10 minutes followed by a 10 minute interval before another
1 mg dose given if AF had not converted by that time.
Ibutilide administration is stopped immediately if conversion
to sinus rhythm has occurred.
Data analysis
Student’s t test was used for comparison between groups. A
p value ,0.05 was considered significant. Data are presented
as mean (SD).
RESULTS
Ibutil ide group
A total of 22 patients (mean (SD) age 55 (13) years; 20 men)
with AF received ibutilide. The mean rate of the AF was 137
(24) bpm. In all patients the duration of symptoms was less
than seven days. Ten patients received two doses of 1 mg
each whereas 12 required only 1 mg. Fourteen patients (64%)
converted to sinus rhythm, all within one hour of the initial
infusion (fig 1). The mean QTc interval after conversion in the
14 patients was 420 (28) ms and there were no instances of
torsades de pointes or other complications. All were
discharged from the ED without incidence after four hours.
Rate control group
A total of 24 patients (mean age 71 (12) years; 11 men) with
AF received no membrane active antiarrhythmics but only
rate control drugs. Of these, eight received a b blocker only,
four received calcium channel blockers, and nine received
digoxin. Two patients were given both a b blocker and
digoxin and one received both a b blocker and a calcium
channel blocker. In all patients the duration of the
arrhythmia was less than seven days. The mean rate of AF
was 126 (26) bpm (p = not significant compared with
ibutilide). Seven of the 24 patients (29%) converted to sinus
rhythm within 12 hours (p,0.005, compared with conver-
sion rate at one hour with ibutilide). The mean QTc interval
in those who converted was 377 (28) ms (p,0.05, compared
133
www.emjonline.com
 on 20 December 2007 emj.bmj.comDownloaded from 
to ibutilide) and there was one incidence of severe
bradycardia following administration of digoxin.
DISCUSSION
The main results of our study suggest that ibutilide is more
successful than rate control drugs in early restoration of sinus
rhythm in recent onset AF. Ibutilide appears to be a safe drug
to use in the ED setting.
AF is probably the commonest arrhythmia in the ED. Many
patients will have had AF for less than 48 hours and are
therefore candidates for cardioversion without preceding
anticoagulation. Early restoration of sinus rhythm in this
group of patients is important and feasible.1 Electrical
cardioversion is frequently used to restore sinus rhythm but
requires that patients are fasting. There is also an added cost
of anaesthesia. Pharmacological cardioversion, however, may
be attempted even if the patient is non-fasting.
A number of drugs have been found effective for rapid
cardioversion of AF. A recently published meta-analysis
concluded, albeit from a limited number of comparative
studies, that flecainide was superior to many of the other
antiarrhythmic drugs in this respect.4 Flecainide has a
conversion rate of 57–68% at two to four hours after drug
administration.5 Ibutilide is a recent addition to the
armamentarium of drugs for pharmacological cardioversion
of AF and has been shown to be superior to both
procainamide and sotalol for this purpose.6 7
The rate of success of ibutilide in our study was 64% in the
first hour after administration of the first dose which is
comparable with what is reported with flecainide. A recently
published study comparing ibutilide and flecainide found
their efficacy to be comparable.8 As a result of strict exclusion
criteria for ibutilide administration no complications were
seen in the this group. Patients were observed in a monitor
for four hours after administration of ibutilide and then
discharged, with no problems reported after discharge.
There are several limitations to this study. The data
collection was done retrospectively and therefore the patients
were not randomised. The groups are thus not identical and
the patients in the rate control group were older than those in
the ibutilide group. Consequently, patients in the rate control
group may conceivably have had more comorbidities.
Conclusion
Ibutilide is effective for converting recent onset AF in patients
presenting to the ED and is an alternative for cardioversion in
those patients who are non-fasting and therefore are not
candidates for immediate electrical cardioversion. Ibutilide
has a rapid mode of action with a high rate of conversion in
the first hour after drug administration. The main potential
drawback of the drug is the risk of torsades de pointes.
However, as our study shows, the incidence of complications
is low in selected patients and the drug can be safely used in
the ED setting.
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Figure 1 Rate of conversion to sinus rhythm with ibutilide versus rate
control drugs.
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